İçeriğe geç
akaturk Akademik ölçüm
Giriş yap Kayıt ol

Akademisyen

OZAN YAZICI

PROFESÖR

GAZİ ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

Araştırma konuları OpenAlex
Akademik özet YÖKSİS ve OpenAlex ayrı sayılır.
Makale 251
YÖKSİS251 OpenAlex0
Proje 24
Kitap 23
Bildiri 497

Atıf etkisi

OpenAlex YÖKSİS makalelerinden OpenAlex’te eşleşen: 111
h-indeks 14 Türkiye yüzdelik dilimi: 93 Büyük işbirlikleri hariç: h 13 · 2 makale Üniversitesinde h-indekse göre 96. / 1.484
i10-indeks
22
Toplam atıf
892
Türkiye’de üst %5,4
Makale başına
8,0
FWCI
1,88
1,00 = dünya ortalaması
Dünyada üst %1
3
Dünyada üst %10
9

En çok atıf alan makaleleri

  1. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group 2023 dünyada üst %1 161 atıf
  2. Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC 2025 dünyada üst %1 126 atıf
  3. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy 2021 dünyada üst %10 41 atıf

h-indeks ve atıflar, bu akademisyenin YÖKSİS makalelerinden OpenAlex’te eşleşenlerin atıf sayılarından hesaplanır (Google Scholar, WoS veya Scopus değildir). Eşleşmeyen makalelerin atıfı dahil değildir.

Alan sıralaması

YÖKSİS ?

Dizin çeyrekleri

?
Scopus (SJR) 199
  • Q1 71
  • Q2 54
  • Q3 57
  • Q4 20
WoS (JCR) 192
  • Q1 50
  • Q2 34
  • Q3 45
  • Q4 65
TR Index TR Index

41 makale

OpenAlex atıf yüzdelik
  • Üst %1 3
  • Üst %10 24
  • Ort. 60.0%
  • n 177
Diğer sayımlar

Scopus (SJR)

  • Özet hariç 197 Q1 69 Q2 54 Q3 57 Q4 20
  • En iyi Q 199 Q1 71 Q2 53 Q3 56 Q4 19
  • YÖKSİS satırı 399

WoS (JCR)

  • Özet hariç 190 Q1 48 Q2 34 Q3 45 Q4 65
  • En iyi Q 192 Q1 50 Q2 34 Q3 45 Q4 63
  • YÖKSİS satırı 381

TR Index

  • YÖKSİS satırı 76 makale

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Yayını olan dergiler

126 dergi

İlk 80 dergi gösteriliyor (toplam 126).

Scopus (SJR)
Q1 71 Q2 54 Q3 57 Q4 20
WoS (JCR)
Q1 50 Q2 34 Q3 45 Q4 65
TR Index
41 makale

Makale listesi

  1. 2026 Real-world comparison of cabozantinib and sunitinib inadvanced non-clear cell renal cell carcinoma: A multicenterstudy by the Turkish Oncology Group INTERNATIONAL JOURNAL OF CANCER DOI 10.1002/ijc.70165Int. YÖKSİS SJR Q1 JCR Q2
  2. 2025 Does lifestyle and physical activity redefine the paradigm in lung cancer management? Supportive Care in Cancer DOI 10.1007/s00520-025-09588-2 YÖKSİS SJR Q1 JCR Q1
  3. 2025 Splenic index score as a predictor of outcomes in metastatic non small cell lung cancer patients treated with immune checkpoint inhibitors Scientific Reports DOI 10.1038/s41598-025-00708-w YÖKSİS SJR Q1 JCR Q1 OpenAlex 85.0%
  4. 2025 Carcinoma erysipeloides, a case-report and review of the sixty-nine cases in the literature The American Journal of the Medical Sciences DOI 10.1016/j.amjms.2024.10.008 2 YÖKSİS kaydı YÖKSİS SJR Q2 JCR Q2
  5. 2025 Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical Observations Medicina DOI 10.3390/medicina61061029 YÖKSİS SJR Q2 JCR Q1
  6. 2025 Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer Cancer Investigation DOI 10.1080/07357907.2025.2598042 YÖKSİS SJR Q3 JCR Q3 OpenAlex 52.8%
  7. 2025 Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience BMC Cancer DOI 10.1186/s12885-025-15181-x 2 YÖKSİS kaydı YÖKSİS SJR Q2 JCR Q2 OpenAlex 75.6%
  8. 2025 Evaluation of 30-day mortality rate following intravenous systemic anticancer therapy: a retrospective analysis BMC Cancer DOI 10.1186/s12885-025-14513-1 YÖKSİS SJR Q2 JCR Q2 OpenAlex 81.0%
  9. 2025 Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX The Lancet Oncology DOI 10.1016/S1470-2045(25)00341-9 YÖKSİS SJR Q1 JCR Q1
  10. 2025 Effect of a ChatGPT-based digital counseling intervention on anxiety and depression in patients with cancer: A prospective, randomized trial European Journal of Cancer DOI 10.1016/j.ejca.2025.115408 YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.4%
  11. 2025 Comparison of clinicopathological features in early-onset breast cancer patients with and without pathogenic genetic mutation. Journal of Clinical Oncology DOI 10.1200/JCO.2025.43.16_suppl.e13179 YÖKSİS SJR Q1 JCR Q1
  12. 2025 Efficacy and safety of neoadjuvant FLOT treatment for resectable gastric/gastroesophageal junction adenocarcinoma in Turkish and German patients; a real-world data BMC Cancer DOI 10.1186/s12885-025-15043-6 YÖKSİS SJR Q2 JCR Q2
  13. 2025 Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study Annals of Saudi Medicine DOI 10.5144/0256-4947.2025.249 2 YÖKSİS kaydı YÖKSİS SJR Q3 JCR Q2 OpenAlex 82.6%
  14. 2025 Attenuated Form of Nijmegen Breakage Syndrome: Case Report of the Oldest Patient American Journal of Medical Genetics Part A DOI 10.1002/ajmg.a.64170 YÖKSİS SJR Q2 JCR Q4
  15. 2025 Olfactory Effects of Chemotherapy Combined with Bevacizumab on Advanced-Stage Colorectal Cancer Patients Indian Journal of Otolaryngology and Head and Neck Surgery DOI 10.1007/s12070-024-05307-1 YÖKSİS SJR Q3 JCR Q4 OpenAlex 0.1%
  16. 2025 Prognostic value of HER2 2 + expression in patients with TNBC receiving adjuvant capecitabine Clinical and Translational Oncology DOI 10.1007/s12094-024-03812-x YÖKSİS SJR Q2 JCR Q3
  17. 2025 Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC New England Journal of Medicine DOI 10.1056/NEJMoa2503001 YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%
  18. 2025 Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study Scientific Reports DOI 10.1038/s41598-025-19899-3 YÖKSİS SJR Q1 JCR Q1 OpenAlex 34.0%
  19. 2025 Prognostic Nutritional Index as a Biomarker in Metastatic Hormone‐Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization The Prostate DOI 10.1002/pros.24876 YÖKSİS SJR Q1 JCR Q2 OpenAlex 14.7%
  20. 2025 Modification of the novel RANO clinical risk score for low- and middle-income countries without access to MGMT methylation testing. Journal of Clinical Oncology DOI 10.1200/JCO.2025.43.16_suppl.2052 YÖKSİS SJR Q1 JCR Q1

Akademisyenlere dön